NASDAQ:MCRBSeres Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Seres Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $6.20 +0.66 (+11.92 %) (As of 05/26/2020 04:00 PM ET) Add Compare Share Today's Range$5.70Now: $6.20▼$6.5950-Day Range$3.04MA: $4.11▼$5.5352-Week Range$2.02Now: $6.20▼$6.59Volume845,538 shsAverage Volume312,062 shsMarket Capitalization$449.75 millionP/E RatioN/ADividend YieldN/ABeta0.98 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome. The company's advanced program is the SER-109, which is in Phase III clinical development for reducing recurrent clostridium difficile infection (CDI). It is also developing SER-287 that is in Phase IIb study in patients with active mild-to-moderate ulcerative colitis; and SER-401, which is in Phase Ib study in metastatic melanoma to augment the efficacy of anti-PD-1 immunotherapy. In addition, the company engages in the development of SER-301, an Ecobiotic microbiome therapeutic candidate for the treatment of inflammatory bowel disease; and SER-109, a donor-derived purified bacterial spore-based microbiome therapeutic candidate that is in Phase III clinical trial to correct dysbiosis in the colonic microbiome in the setting of recurrent CDI. Further, it is developing SER-262, a multi-strain Ecobiotic microbiome therapeutic candidate, which is in Phase Ib study for CDI antibiotic treatment; and SER-155, a microbiome therapeutic candidate to correct dysbiosis in patients following allogeneic hematopoietic stem cell or solid organ transplants. The company has license and collaboration agreement with Nestec Ltd. and Memorial Sloan Kettering Cancer Center, as well as collaboration with AstraZeneca. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.Read More Beat the Market (BTM) Rank™ 2.4 Analyst's Opinion Consensus RatingSeres Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.50, Seres Therapeutics has a potential upside of 21.1% from its current price of $6.20.Amount of Analyst CoverageSeres Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Community Rank Outperform VotesSeres Therapeutics has received 473 “outperform” votes. (Add your “outperform” vote.)Underperform VotesSeres Therapeutics has received 324 “underperform” votes. (Add your “underperform” vote.)Community SentimentSeres Therapeutics has received 59.35% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Seres Therapeutics and other stocks. Vote “Outperform” if you believe MCRB will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MCRB will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldSeres Therapeutics does not currently pay a dividend.Dividend GrowthSeres Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Seres Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.80% of the stock of Seres Therapeutics is held by insiders.Percentage Held by Institutions93.42% of the stock of Seres Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Seres Therapeutics are expected to decrease in the coming year, from ($1.01) to ($1.08) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Seres Therapeutics is -6.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Seres Therapeutics is -6.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 2.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.28 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MCRB Previous Symbol CUSIPN/A CIK1609809 Webwww.serestherapeutics.com Phone617-945-9626Debt Debt-to-Equity RatioN/A Current Ratio1.83 Quick Ratio1.83Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$34.51 million Price / Sales13.03 Cash FlowN/A Price / Cash FlowN/A Book Value($0.69) per share Price / Book-8.98Profitability EPS (Most Recent Fiscal Year)($1.20) Net Income$-70,280,000.00 Net Margins-186.09% Return on EquityN/A Return on Assets-51.30%Miscellaneous Employees145 Outstanding Shares72,599,000Market Cap$449.75 million Next Earnings Date8/4/2020 (Estimated) OptionableOptionable NASDAQ:MCRB Rates by TradingView Receive MCRB News and Ratings via Email Sign-up to receive the latest news and ratings for MCRB and its competitors with MarketBeat's FREE daily newsletter. Seres Therapeutics (NASDAQ:MCRB) Frequently Asked Questions How has Seres Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Seres Therapeutics' stock was trading at $2.64 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, MCRB stock has increased by 134.7% and is now trading at $6.1950. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Seres Therapeutics? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Seres Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Seres Therapeutics. When is Seres Therapeutics' next earnings date? Seres Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Seres Therapeutics. How were Seres Therapeutics' earnings last quarter? Seres Therapeutics Inc (NASDAQ:MCRB) released its quarterly earnings data on Thursday, May, 7th. The biotechnology company reported ($0.28) EPS for the quarter, meeting analysts' consensus estimates of ($0.28). The biotechnology company had revenue of $8.19 million for the quarter, compared to analysts' expectations of $8.01 million. View Seres Therapeutics' earnings history. What price target have analysts set for MCRB? 6 Wall Street analysts have issued twelve-month target prices for Seres Therapeutics' stock. Their forecasts range from $4.00 to $11.00. On average, they expect Seres Therapeutics' share price to reach $7.50 in the next year. This suggests a possible upside of 21.1% from the stock's current price. View analysts' price targets for Seres Therapeutics. Has Seres Therapeutics been receiving favorable news coverage? News articles about MCRB stock have been trending negative recently, InfoTrie reports. The research group identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Seres Therapeutics earned a coverage optimism score of -2.2 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news aboutSeres Therapeutics. Are investors shorting Seres Therapeutics? Seres Therapeutics saw a increase in short interest in May. As of May 15th, there was short interest totaling 5,590,000 shares, an increase of 9.6% from the April 30th total of 5,100,000 shares. Based on an average trading volume of 320,700 shares, the short-interest ratio is currently 17.4 days. Currently, 13.1% of the shares of the stock are short sold. View Seres Therapeutics' Current Options Chain. Who are some of Seres Therapeutics' key competitors? Some companies that are related to Seres Therapeutics include Arvinas (ARVN), Zogenix (ZGNX), Eidos Therapeutics (EIDX), Ligand Pharmaceuticals (LGND), Theravance Biopharma (TBPH), Dicerna Pharmaceuticals (DRNA), Opko Health (OPK), Heron Therapeutics (HRTX), Arcus Biosciences (RCUS), Zymeworks (ZYME), INDIVIOR PLC/S (INVVY), Akebia Therapeutics (AKBA), CytoDyn (CYDY), Constellation Pharmaceuticals (CNST) and Y-mAbs Therapeutics (YMAB). View all competitors. What other stocks do shareholders of Seres Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Seres Therapeutics investors own include Opko Health (OPK), TherapeuticsMD (TXMD), Juno Therapeutics (JUNO), Walt Disney (DIS), NVIDIA (NVDA), Alibaba Group (BABA), Novavax (NVAX), BioCryst Pharmaceuticals (BCRX), Exelixis (EXEL) and Gilead Sciences (GILD). Who are Seres Therapeutics' key executives? Seres Therapeutics' management team includes the following people: Mr. Eric D. Shaff, Pres, CEO & Director (Age 43)Mr. Marcus Chapman, VP of Fin., Principal Financial & Accounting Officer (Age 48)Dr. John G. Aunins, CTO and Exec. VP of Bioprocess & Manufacturing (Age 58)Dr. Matthew R. Henn, Exec. VP & Chief Scientific Officer (Age 44)Mr. Carlo Tanzi, VP of Investor Relations & Corp. Communications When did Seres Therapeutics IPO? (MCRB) raised $101 million in an initial public offering (IPO) on Friday, June 26th 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers. What is Seres Therapeutics' stock symbol? Seres Therapeutics trades on the NASDAQ under the ticker symbol "MCRB." Who are Seres Therapeutics' major shareholders? Seres Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Nikko Asset Management Americas Inc. (11.83%), Nikko Asset Management Americas Inc. (11.83%), Sumitomo Mitsui Trust Holdings Inc. (11.83%), BlackRock Inc. (5.55%), JPMorgan Chase & Co. (1.44%) and Federated Hermes Inc. (1.42%). Company insiders that own Seres Therapeutics stock include Eric D Shaff, John G Aunins, Marcus Chapman, Noubar Afeyan, Roger Pomerantz and Thomas Desrosier. View institutional ownership trends for Seres Therapeutics. Which institutional investors are selling Seres Therapeutics stock? MCRB stock was sold by a variety of institutional investors in the last quarter, including Squarepoint Ops LLC, AXA, Two Sigma Investments LP, BlackRock Inc., Parametric Portfolio Associates LLC, Morgan Stanley, Jane Street Group LLC, and State Street Corp. View insider buying and selling activity for Seres Therapeutics. Which institutional investors are buying Seres Therapeutics stock? MCRB stock was bought by a variety of institutional investors in the last quarter, including Federated Hermes Inc., JPMorgan Chase & Co., Nikko Asset Management Americas Inc., Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., Geode Capital Management LLC, Alliancebernstein L.P., and Two Sigma Advisers LP. View insider buying and selling activity for Seres Therapeutics. How do I buy shares of Seres Therapeutics? Shares of MCRB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Seres Therapeutics' stock price today? One share of MCRB stock can currently be purchased for approximately $6.20. How big of a company is Seres Therapeutics? Seres Therapeutics has a market capitalization of $449.75 million and generates $34.51 million in revenue each year. The biotechnology company earns $-70,280,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis. Seres Therapeutics employs 145 workers across the globe. What is Seres Therapeutics' official website? The official website for Seres Therapeutics is www.serestherapeutics.com. How can I contact Seres Therapeutics? Seres Therapeutics' mailing address is 200 SIDNEY STREET - 4TH FLOOR, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-945-9626 or via email at [email protected] This page was last updated on 5/27/2020 by MarketBeat.com Staff
